Evaluation of efficacy in endoscopic submucosal dissection to early gastric cancer, early esophageal cancer, and/or early pharyngeal cancer by new device "Nanoshooter".

Evaluation of efficacy in endoscopic submucosal dissection to early gastric cancer, early esophageal cancer, and/or early pharyngeal cancer by new device "Nanoshooter". - Evaluation of efficacy in endoscopic submucosal dissection to early gastric cancer, early esophageal cancer, and/or early pharyngeal cancer by new device "Nanoshooter".

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008261

Enrollment

Registered

2012-06-26

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early gastric cancer (gastric adenoma) early esophageal cancer early pharyngeal cancer

Interventions

Nanoshooter (Top)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The inclusion criteria. 1)The patient's age is between 18 and 89 years old. 2)The patient who has diagnosis of early gastric cancer, gastric adenoma, early esophageal cancer, and/or early pharyngeal cancer. 3)Informed Consent. 4)Hospitalization. 5)The patient that contraception is possible during the study.

Exclusion criteria

Exclusion criteria: The exclusion criteria. 1)The patient who repeats hematemesis. 2)The patient who has a history of allergy to the use drug. 3)The patient that the withdrawal of coagulant and/or antiplatelet agent is impossible. 4)The patient with bad physical status. 5)The patient who cannot do to informed consent. 6)The patient who was considered ineligible by the investigators.

Design outcomes

Primary

Measure	Time frame
Efficacy 1)Efficacy in nasal endoscopic submucosal dissection by oral way to early gastric cancer and/or early esophageal cancer. 2)Efficacy in nasal endoscopic submucosal dissection by nasal way to early gastric cancer, early esophageal cancer, and/or early pharyngeal cancer. Safety Treatment time, bleeding, a ratio of perforation, Visual Analog Scale	—

Countries

Japan

Contacts

Public ContactMasakatsu Nakamura

Kanazawa Medical University Department of Gastroenterology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Evaluation of efficacy in endoscopic submucosal dissection to early gastric cancer, early esophageal cancer, and/or early pharyngeal cancer by new device &quot;Nanoshooter&quot;.